MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Immuno-Oncology, Immunotherapy
Genelux Corporation (NASDAQ: GNLX)*
Organization & Developments: Genelux
Parents
Genelux Corporation (NASDAQ: GNLX)*
Children
*Founded to develop treatments for various aggressive or difficult-to-treat solid tumor cancers.
2022: PO Update: Genelux Finalizes $16 Million IPO Plan_seekingalpha.com
2022: The firm's lead candidate is Olvi-Vec, which is in Phase 3 planning phase for the treatment of platinum resistant/refractory ovarian cancer [PRROC] and which has already met a preliminary endpoint for its Phase 2 trial for that disease.
2024: Genelux: H2 2025 PRROC Data Is A Major Inflection Point
Jumps
Finance & Acquisitions: Genelux
Key People: Genelux